Skip to content

    Karyopharm Therapeutics (KPTI) stock price & financials

    View KPTI earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance76.1% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $38.78M
    $30.54M
    $30.02M
    $37.93M
    $44.04M
    +13.6%
    $34.08M
    +11.6%
    $35.07M
    +16.8%
    $33.43M
    -11.9%
    Strengthening
    Operating Profit
    -$26.28M
    -$31.28M
    -$33.26M
    -$24.39M
    -$15.22M
    +42.1%
    -$17.84M
    +43.0%
    -$26.76M
    +19.5%
    -$22.53M
    +7.6%
    Strengthening
    Net Profit
    -$32.07M
    -$30.78M
    -$23.46M
    -$37.25M
    -$33.13M
    -3.3%
    -$102.20M
    -232.0%
    -$22.39M
    +4.6%
    -$67.02M
    -79.9%
    Weakening
    EPS
    $-3.85
    $-2.77
    $-4.32
    $-3.82
    +0.8%
    $-1.02
    +63.2%
    $-2.32
    +46.3%
    Strengthening
    Other Income
    -$5.76M
    $392.0K
    $9.83M
    -$12.82M
    -$17.87M
    -210.2%
    -$84.42M
    -21636.0%
    $4.37M
    -55.6%
    -$44.50M
    -247.0%
    Weakening
    Interest
    $11.38M
    $11.20M
    $10.99M
    $11.23M
    $11.01M
    -3.3%
    $12.62M
    +12.6%
    $12.55M
    +14.2%
    $13.14M
    +17.1%
    Strengthening
    Depreciation
    Profit before Tax
    -$32.04M
    -$30.89M
    -$23.43M
    -$37.21M
    -$33.09M
    -3.3%
    -$102.27M
    -231.1%
    -$22.39M
    +4.4%
    -$67.02M
    -80.1%
    Weakening
    MarginsOPM
    -67.8%
    -102.4%
    -110.8%
    -64.3%
    -34.6%
    +49.0%
    -52.4%
    +48.9%
    -76.3%
    +31.1%
    -67.4%
    -4.8%
    Strengthening
    Tax
    -0.1%
    0.3%
    -0.1%
    -0.1%
    -0.1%
    -11.1%
    0.1%
    -80.0%
    0.0%
    +100.0%
    0.0%
    +100.0%
    Strengthening
    ReturnsROIC
    1.7%
    1.7%
    1.3%
    2.0%
    1.8%
    +3.3%
    5.5%
    +232.0%
    1.2%
    -4.6%
    3.6%
    +79.9%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$118.02M$128.86M$85.92M$190.46M$135.19M$52.23M$62.48M$60.54M$54.98M
    Short-Term Investments
    Total Current Assets$334.61M$278.57M$276.53M$275.61M$350.16M$233.92M$156.46M$103.15M$106.38M
    Net PP&E$3.86M$13.66M$11.58M$9.56M$7.38M$4.88M$6.28M$4.65M$4.35M
    Goodwill
    Intangibles
    Total Assets$341.19M$294.96M$313.05M$305.31M$358.17M$240.44M$164.42M$108.42M$111.32M
    LiabilitiesTotal Current Liabilities$46.90M$46.35M$60.20M$73.72M$65.91M$69.48M$92.26M$92.06M$134.23M
    Short-Term Debt
    Long-Term Debt$169.29M
    Long-Term Leases$13.20M$11.29M$8.97M$6.10M$2.79M$6.71M$5.74M$5.18M
    Total Liabilities$158.02M$245.19M$262.50M$384.98M$374.83M$376.64M$350.44M$401.34M$441.49M
    EquityCommon Stock & APIC$6.0K$7.0K$7.0K$8.0K$12.0K$12.0K$13.0K$14.0K$14.0K
    Retained Earnings-$673.75M-$873.34M-$1.07B-$1.18B-$1.34B-$1.49B-$1.56B-$1.76B-$1.85B
    Total Equity$183.17M$49.77M$50.55M-$79.67M-$16.66M-$136.21M-$186.02M-$292.93M-$330.17M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$159.12M-$190.82M-$160.23M-$107.12M-$149.55M-$92.72M-$127.49M-$75.37M-$65.35M
    Cash from Investing-$107.66M$78.45M-$53.69M$141.84M-$104.26M$7.94M$95.47M$43.38M$2.97M
    Cash from Financing$316.11M$124.31M$172.08M$73.65M$193.74M$1.12M$41.65M$30.05M$78.60M
    SummaryCapital Expenditure-$2.36M-$206.0K-$145.0K-$212.0K-$118.0K$0-$142.0K$0
    Free Cash Flow-$161.48M-$191.03M-$160.38M-$107.33M-$149.67M-$92.72M-$127.63M-$75.37M
    FCF Margin-532.3%-467.1%-148.4%-51.2%-95.3%-63.5%-87.9%-51.6%

    Ratios